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Background: Obesity and diabetes mellitus are well-defined risk factors for cardiovascular mortality. The impact of
antecedent hyperglycemia and body size on mortality in critical ill patients in intensive care units (ICUs) may vary
across their range of values. Therefore, we prospectively analyzed the relationship between in-hospital mortality and
preexisting hyperglycemia and body size in critically ill ICU patients to understand how mortality varied among
normal, overweight, and obese patients and those with low, intermediate, and high glycated hemoglobin
(HbA1c) levels.
Methods: Medical history, weight, height, physiologic variables, and HbA1c were obtained during the first 24 h for
patients who were consecutively admitted to the high complexity ICU of Hospital de Clínicas de Porto Alegre,
Brazil, from April to August 2011. The relationships between mortality and obesity and antecedent hyperglycemia
were prospectively analyzed by cubic spline analysis and a Cox proportional hazards model.
Results: The study comprised 199 patients. The overall hospital mortality rate was 43.2% during a median 16
(8–28) days of follow-up. There was a progressive risk of in-hospital mortality with higher HbA1c levels, with the
relationship becoming significant at HbA1c >9.3% compared with lower levels (hazard ratio 1.74; 95% confidence
interval with Bonferroni correction 1.49–2.80). In contrast, mean body mass index (BMI) was higher in survivors than
in nonsurvivors (27.2 kg/m2 ± 7.3 vs. 24.7 kg/m2 ± 5.0 P = 0.031, respectively). Cubic spline analysis showed that these
relationships differed nonlinearly through the spectrum of BMI values. In a Cox proportional hazards model adjusted
for Acute Physiology and Chronic Health Evaluation II score and HbA1c, the risk of in-hospital mortality progressively
decreased with increasing BMI (BMI <20 vs. 20–23.9 kg/m2, P = 0.032; BMI <20 vs. 24–34.9 kg/m2, P = 0.010; BMI <20
vs. ≥35 kg/m2, P = 0.032).
Conclusions: Our findings suggest that significant hyperglycemia prior to ICU admission is a risk factor for
in-hospital mortality. Conversely, increasing BMI may confer an advantageous effect against mortality in critical
illness independently of previous glycemic control.
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Diabetes mellitus (DM) and obesity are well-defined risk
factors for cardiovascular disease and mortality [1,2].
Both diseases have assumed epidemic proportions in the
last few decades [1,3]. As a consequence, the increasing
rates of admission of patients with obesity and/or DM to
intensive care units (ICUs) have become a concern for
intensivists [4].
A large body of evidence has defined poor glycemic
control as a negative prognostic factor in critical illness
[5,6]. This association is especially true in patients with-
out a past known history of DM, but is poorly defined in
those with known DM [7-9]. It is also unclear how gly-
cemic control before ICU admission affects prognosis in
critically ill patients.
The measurement of glycated hemoglobin (HbA1c) levels
is widely employed to estimate average glucose levels over
a 2- to 3-month period, providing a method for the assess-
ment of past glycemic control [10]. Recently, the American
Diabetes Association (ADA) proposed the use of HbA1c
levels for the diagnosis of prediabetes and DM [11]. Be-
cause HbA1c reflects past glycemic control, it can be used
to understand the relationship between prior hypergly-
cemia and morbidity and mortality in recently admitted
critically ill patients [10,11]. Recent data have linked higher
HbA1c levels to increased ICU mortality [12].
Obesity is considered a risk factor for the development
of DM [1,3]. The impact of obesity as a prognostic factor
in critically ill patients is controversial, and possibly in-
fluenced by the presence of DM [13]. Findings to date
are not conclusive, with some studies reporting no asso-
ciation between obesity and mortality [14,15], and others
finding that low body mass index (BMI) is associated
with increased mortality [15-17], or that excess weight is
a negative prognostic factor [18,19]. Two meta-analyses
pooling data on studies evaluating the impact of obesity
on outcomes in ICU patients did not find an association
between obesity and mortality in critical illness [20,21].
However, data analyzing the effect of glycemic status
and body size on survival in ICU patients across the
spectrum of body size and glycemic status may give the
opportunity to better understand the complex relation-
ship between hyperglycemia, excess weight, and survival
in critical illness. To address this issue, we investigated
whether preexisting hyperglycemia and body size are de-
terminants of morbidity and mortality in patients re-
cently admitted to the ICU.
Methods
Study design
This was a prospective observational study carried out
in the ICU of Hospital de Clínicas de Porto Alegre, an
850-bed teaching hospital of Federal University of Rio
Grande do Sul, Brazil. Written informed consent wasobtained from each participant (or surrogate), and the
study was approved by Research Ethics Committee of
Hospital de Clínicas de Porto Alegre. No patients (or
surrogate) refused to participate in the study.
Study population and data source
Consecutive medical and surgical patients aged ≥18 years
who were first admitted to the ICU between April 1, 2011,
and August 22, 2011, were eligible for inclusion. Patients
with hyperglycemic crisis (diabetic ketoacidosis or hyper-
osmolar hyperglycemic states) and those with hemoglo-
binopathies were excluded.
Clinical and demographic data were collected at baseline,
including a detailed past medical history, data regarding
corticosteroid and vasopressor therapy, mechanical ventila-
tion support, and renal replacement therapy. Physiologic
and laboratory data were collected for calculation of Acute
Physiology and Chronic Health Evaluation (APACHE) II
and Sequential Organ Failure Assessment (SOFA) scores
[22,23]. Supine height (cm) and weight (kg), as measured
routinely on ICU admission, were used to calculate BMI,
expressed as weight (kg)/height2 (m).
Glucose (hexokinase assay), ultrasensitive C-reactive pro-
tein (enzymatic colorimetric assay), lactate (turbidimetric
method), and HbA1c (high-performance liquid chromatog-
raphy using Tosoh 2.2 Plus HbA1c; Tosoh Corporation,
Tokyo, Japan) were measured within 24 h of ICU ad-
mission. The HbA1c method was certified by the National
Glycohemoglobin Standardization Program (NGSP)
(http://www.ngsp.org/critsumm.asp) and values were Inter-
national Federation of Clinical Chemistry and Laboratory
Medicine (IFCC)-aligned. The Hospital de Clínicas de
Porto Alegre Clinical Pathology Department is a partici-
pant in and meets the standards of the HbA1c external
quality assurance program [24].
Based on HbA1c levels, patients were categorized ac-
cording to ADA criteria as having normal glucose toler-
ance (<5.7%), prediabetes (5.7–6.4%), or DM (≥6.5%) [11].
Patients with a known history of DM were classified as
having DM regardless of HbA1c levels. Patients were di-
vided into four BMI categories, according to World Health
Organization definitions: underweight (BMI <18.5 kg/m2),
normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI
25–29.9 kg/m2), class I and II obesity (BMI 30–39.9 kg/
m2), and extreme obesity (BMI >40 kg/m2) [25].
Data analysis and statistical methods
Statistical analyses were performed using PASW Statistics
18 and R 2.13.2 (R Foundation for Statistical Computing,
Vienna, Austria). Data are presented as means ± standard
deviation, median (interquartile range), or absolute and
relative frequencies (%). To compare demographic, clinical
and laboratory data, the Student t-test for independent
samples, Mann–Whitney U, or chi-square tests were used
Table 1 Clinical and laboratory characteristics according
to survival
Survivors Nonsurvivors P
(n = 113) (n = 86)
Age (years) 56 ± 17.4 61 ± 17 0.052
Males 65 (57. 5) 46 (53.5) 0.570
Days in hospital before
ICU admission
2.5 (1–8) 6 (1–16) <0.001
APACHE II 17.6 ± 7.9 24.8 ± 7.8 <0.001
SOFA 5 (2– 9) 8 (6 –13) <0.001
Comorbidities
COPD 20 (18) 12 (14) 0.443
CHF 12 (10.8) 9 (10.5) 0.938
HIV 6 (5.4) 7 (8.1) 0.443
Body mass index (kg/m2) 27.2 ± 7.3 24.7 ± 5 0.031
History of DM 26 (23) 24 (27.9) 0.430
Glucose tolerance 0.359
Normal 51 (45.1) 41 (47.7)
Prediabetes 40 (35.4) 23 (26.7)
Diabetes 22 (19.5) 22 (25.6)
HbA1c (%) 5.7 (5.3–6.3) 5.8 (5.2–6.5) 0.729
Serum glucose (mg/dL) 122 (99–160) 120 (95–167) 0.909
Lactate (mg/dL) 9.0 (6.3–15.3) 18 (0–35) <0.001
C-reactive protein (mg/dL) 87 (27.5–150.4) 102 (44 –234) 0.067
Mechanical ventilation 69 (61.1) 68 (79.1) 0.008
Hemodialysis 15 (13.3) 30 (34.9) <0.001
Vasopressor support 39 (34.5) 64 (74.4%) <0.001
Data are expressed as mean ± standard deviation, median (interquartile range),
or n (%). COPD, chronic obstructive pulmonary disease; CHF, congestive heart
failure; HIV, human immunodeficiency virus. To convert glucose from mg/dl to
mmol/L, multiply by the factor 0.005. To convert lactate from mg/dL to mmol/L,
multiply by the factor 0.111.
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or Spearman correlation coefficients. Kaplan–Meier event-
free survival curves were used to compare the probability
of in-hospital mortality according to different BMI strata.
Cox regression models and the additional fit of cubic
splines with four knots were used as exploratory data
analysis for visual assessment of the functional relationship
between BMI, HbA1c and mortality while adjusting for
APACHE II score [26-28]. The tested cutoff points for BMI
were from 20 to 35, with increments of 0.5. For each in-
crement, the study sample was divided into two groups
defined by being lower or higher than the cutoff point
and Cox proportional hazards models were used to
estimate the risk of in-hospital mortality (dependent
variable) for each stratum. The spline was then adjusted
with the estimated risks to provide a better understanding
of the relationship with BMI and HbA1c levels. In
addition, 95% confidence intervals for the fitted curve
were calculated with a Bonferroni correction. A two-tailed
P value <0.05 was considered significant.
Results
Patient profile
The study group comprised 199 patients, of whom 111
(55.8%) were men and 88 (44.2%) were women. The
overall in-hospital mortality rate was 43.2% during a
median of 16 (8–28) days of follow-up. Table 1 lists the
characteristics of all study patients and compares survi-
vors and nonsurvivors. The two groups did not differ re-
garding gender, comorbidities, history of DM, glucose
tolerance, or HbA1c levels. The number of days in hos-
pital prior to ICU admission, APACHE and SOFA scores
and plasma lactate levels, as well as the proportion of
patients requiring mechanical ventilation, hemodialysis
and vasopressor support, were higher among nonsurvi-
vors than among survivors. Age and C-reactive protein
levels also tended to be higher, while BMI was lower in
nonsurvivors in comparison to survivors.
A total of 149 (74.9%) patients had no known history
of DM. However, a significant proportion of these seemed
to have previously abnormal glucose metabolism (51
[34.2%] with prediabetes and 16 [10.7%] with DM). BMI
was indicative of normal weight in 43.7% of patients. Ex-
cess weight was observed in 50.3% of the sample (33.1%
overweight, 13.2% obese, and 4% extremely obese), whereas
6% were underweight.
Relationship between glycemic control before ICU
admission, total hemoglobin, body size, and prognostic
factors for mortality
Because the relationship between HbA1c and mortality
could be confounded by BMI, anemia or other factors,
the correlations of HbA1c with total hemoglobin, BMI,
and severity scores were analyzed. There was a weakcorrelation of HbA1c with hemoglobin levels (r
2 = 0.026;
P = 0.025) and BMI (r2 = 0.05; P = 0.007). HbA1c was not
related to plasma lactate (r2 = 0.01; P = 0.135) or C-
reactive protein levels (r2 < 0.01; P = 0.050), nor to APA-
CHE II (r2 < 0.01; P = 0.958) and SOFA scores (r = 0.01;
P = 0.449).
Body size, as estimated by BMI, was also not related to
plasma lactate (r2 < 0.01; P = 0.352), C-reactive protein
(r2 = 0.01; P = 0.196), APACHE II (r2 < 0.01; P = 0.334),
or SOFA (r2 < 0.01; P = 0.634) scores.
Relationship between HbA1c, body size and morbidity
Using HbA1c to classify patients as having normal glucose
tolerance, prediabetes, or DM, we were able to analyze
whether increasingly abnormal glucose metabolism was re-
lated with increasing ICU morbidity. There were no glucose
metabolism-related differences in the need for mechanical
ventilation (normal vs. prediabetes vs. DM, P = 0.894), vaso-
pressor support (normal vs. prediabetes vs. DM, P = 0.460),
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DM, P = 0.583). These requirements also did not differ
from the lowest to the highest BMI strata.Relationship between chronic glycemic control, body size,
and mortality
There was no difference in HbA1c levels between survi-
vors and nonsurvivors (Table 1). When only the sub-
group of patients with a known history of DM were
analyzed, there was also no difference in HbA1c levels
between survivors and nonsurvivors (6.70% [5.8–8.5] vs.
6.8% [5.9–8.1]; P = 0.846).
Cubic spline analysis was used to better analyze the rela-
tionship between HbA1c, BMI, and hospital mortality
during follow-up. This statistical approach enabled graph-
ical quantification of how the risk of hospital mortality
(expressed as hazard ratio [HR]) varied across different
HbA1c and BMI levels. The risk of hospital mortality was
significantly increased in patients with HbA1c levels ≥9.3%
compared with those with lower HbA1c levels (Figure 1).
Nevertheless, the relationship between BMI and risk of
hospital mortality was nonlinear. Patients with a BMI be-
tween 24 and 30 kg/m2 did not exhibit increased hospital
mortality (Figure 2). In-hospital mortality was higher
among those with BMI in the 20–24 kg/m2 range and
lower among those with BMI >30 kg/m2. For example, at
lower body sizes, patients with BMI <23 kg/m2 had a 40%
higher risk of in-hospital mortality (HR = 1.4) as com-





















Figure 1 Adjusted hazard ratio for hospital mortality at various
HbA1c levels. Hazard ratios >1 are indicative of higher risk for
those with higher HbA1c levels. Dashed lines represent the 95%
confidence interval for each HbA1c level. Results were obtained by
multivariate Cox regression with cubic splines with four knots of
HbA1c adjusted for APACHE II scores.higher body size, those with BMI <33 kg/m2 had twice
the risk of in-hospital mortality (HR = 2.0) compared
with those with BMI ≥ 33 kg/m2. The lowest in-hospital
mortality was observed among the patients with the
highest BMIs (Figure 2).
Based on these findings (Figure 2), we stratified the study
sample into four groups by BMI (group 1, BMI <20 kg/m2;
group 2, 20–23.9 kg/m2; group 3, 24–34.9 kg/m2; group
4, ≥35 kg/m2) and compared them by multivariate Cox
regression analysis. In comparison with group 1, mortal-
ity progressively decreased with increasing BMI while
adjusting for HbA1c and APACHE II score (P = 0.032;
Figure 3).
Discussion
Our findings suggest a nonlinear relationship between
glycemic control before ICU admission, body size, and
in-hospital mortality. The risk of the in-hospital mortal-
ity significantly increases with HbA1c levels above 9.3%.
It also progressively increases in patients with a BMI
below 24 kg/m2, having no association with mortality in
overweight patients, while progressively declining in
those with a BMI above 35 kg/m2. The weak correlation
between HbA1c and BMI suggests an independent effect
of these metabolic parameters as prognostic factors in
critically ill patients.
Previous studies suggest that increased HbA1c levels
are a negative prognostic marker in patients with DM
admitted to an ICU [12]. As DM is usually asymptom-
atic in its early stages, many patients may not be aware
of this condition on ICU admission [29]. In our sample,
44.9% of participants with abnormal glucose metabolism
had no previous history of prediabetes or DM. In a retro-
spective study, preexisting hyperglycemia affected the rela-
tionship between acute blood glucose levels and mortality,
suggesting a significant interaction between chronic and
acute glycemic control [9]. In our study using Cox regres-
sion models incorporating a cubic spline with four knots,
we were able to detect an increased risk of mortality in
those with significant hyperglycemia (HbA1c above 9.3%).
However, in the retrospective study, HbA1c levels >7.0%
with less stringent glycemic control were associated with
decreased mortality [9].
Although our data do not suggest that body size inter-
acts with past glycemic control to determine hospital
mortality, BMI was significantly associated with mortal-
ity. Our findings confirm those of other studies that
suggest an inverse relationship between body size and
mortality in critically ill patients [15,16,30,31]. We ana-
lyzed whether this finding could be explained by other
factors such as the requirement for mechanical ventila-
tion, renal replacement therapy or vasopressor support,
and our data suggest the BMI/mortality relationship is
independent of these interventions.
Figure 2 Adjusted hazard ratio at various BMI levels. The risk of hospital mortality is found when the hazard ratio expressed as mean (empty
circle) and 95% confidence interval (dashed lines) do not cross 1. A hazard ratio >1 is indicative of increased risk for those with BMI lower than
that chosen for analysis.
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admitted to the ICU are unclear. One hypothesis is that
obese patients have a lower threshold for ICU admission
as compared with normal-weight patients. Consequently,
obese patients may have a better prognosis at ICU ad-
mission. However, we found that mortality differences






Figure 3 Survival curves stratified by BMI. Kaplan–Meier survival curves
BMI <20 vs. 20–23.9 kg/m2, P = 0.032; BMI <20 vs. 24–34.9 kg/m2, P = 0.010;protection against in-hospital death after adjusting for
APACHE II scores. We are aware that APACHE may be
artificially elevated in obesity (increased creatinine levels
despite normal renal function, and decreased oxygen-
ation because of lung atelectasis); however, there are no
prognostic scores validated for use in the obese critically
ill. Cubic spline analysis, which allowed analysis of howstratified by BMI and adjusted for APACHE II scores and HbA1c.
BMI <20 vs. ≥35 kg/m2, P = 0.032.
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tion of the study sample, suggests that this relationship
is not linear.
However, the high mortality for underweight and low-
normal weight patients might be explained by the previ-
ous nutrition status, which is a finding more consistent
in the literature [15,30], and suggests that special atten-
tion to the nutrition of this group of patients is needed.
There are some limitations to this study. First, HbA1c
levels were available to all healthcare providers involved
in the care of the study patients and whose actions could
affect patient management. However, at the study hos-
pital, ICU staff follow a protocol with very well-known
targets for acute glycemic control, as proposed in recent
guidelines, which do not routinely take HbA1c into ac-
count [32]. Second, body size was measured by the team
involved in patient care at the ICU, which may have re-
sulted in some variability in body size measurement. Al-
though we did not perform a more sophisticated analysis
of body size composition, such as bioelectric impedance,
BMI was measured upon admission at ICU, therefore
probably reducing the impact of fluid overload in body
size determination. Moreover, the staff are well trained
in measuring weight and height. Third, few patients had
extreme obesity, which hindered quantification of the
impact of BMI >40 kg/m2 on mortality. However, a re-
cent study suggested no increased risk of mortality in
patients with extreme obesity versus those with normal
weight [33]. Fourth, we had a high mortality rate, as
would be expected for severely ill patients. The expected
mortality for our median APACHE II score of 21 is 38%,
which was similar to the study overall hospital mortality
of 43.2% [22].Conclusions
This study has shown that preexisting hyperglycemia
(HbA1c >9.3%) increases the risk of hospital mortality in
critically ill patients. Moreover, underweight and low-
normal weight patients exhibited a decreased survival
rate compared with those who were overweight. Obesity,
however, was associated with decreased mortality in crit-
ical ill patients. As the prevalence of DM and obesity
continue to increase globally, intensivists will require a
better understanding of the impact of these conditions
in the ICU setting, and will need to develop strategies to
improve the care of these patients. Further studies are
required for the construction of a strategy for the man-
agement of patients with hyperglycemia and obesity in
the ICU.
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